Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
NCT ID: NCT06152991
Last Updated: 2023-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE3
196 participants
INTERVENTIONAL
2023-09-25
2027-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Godex® is being investigated for its potential to contribute to a reduction in liver fat content and improvement in liver fibrosis when administered over an extended period in patients with NAFLD. Additionally, this study aims to confirm the normalization of HbA1c and ALT, as observed in previous research, and to verify the reduction in intrahepatic fat content through MRI-PDFF analysis and improvement in liver fibrosis via MRE assessment. This investigation is motivated by the insufficient preliminary research on the long-term prescription of Godex® for NAFLD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Group
Oral administration of 2 capsules of Godex® three times a day (tid) for 96 weeks
GODEX
The amount of active ingredient per dose (1 capsule)
* Carnitine Orotate 150mg
* liver extract antitoxic fraction 12.5㎎
* Adenine Hydrochloride 2.5mg
* Pyridoxine Hydrochloride 25mg
* Riboflavin 0.5mg
* Cyanocobalamin 0.125mg
* Biphenyl Dimethyl Dicarboxylate 25mg
Control Group
Oral administration of 2 placebo capsules three times a day (tid) for 96 weeks
Placebo
* Anhydrous lactose 50mg.
* Colloidal silicon dioxide 12mg.
* Amorphous cellulose 50mg.
* Lactose monohydrate 215.625mg.
* Magnesium stearate 7mg.
* Upper and lower brown opaque capsules 77mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GODEX
The amount of active ingredient per dose (1 capsule)
* Carnitine Orotate 150mg
* liver extract antitoxic fraction 12.5㎎
* Adenine Hydrochloride 2.5mg
* Pyridoxine Hydrochloride 25mg
* Riboflavin 0.5mg
* Cyanocobalamin 0.125mg
* Biphenyl Dimethyl Dicarboxylate 25mg
Placebo
* Anhydrous lactose 50mg.
* Colloidal silicon dioxide 12mg.
* Amorphous cellulose 50mg.
* Lactose monohydrate 215.625mg.
* Magnesium stearate 7mg.
* Upper and lower brown opaque capsules 77mg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with elevated liver enzymes (AST or ALT ≥ 60 or sustained AST or ALT ≥ 40 to 59 for 3 months or more).
3. For diabetic patients, those with an HbA1c level of less than 8.5% and no changes in the type and dosage of antidiabetic medications in the past 12 weeks.
4. Patients with an MRI-PDFF ≥ 7% indicating evidence of intrahepatic fat deposition, suspected of having non-alcoholic fatty liver disease.
5. Patients who voluntarily consent to participate in this clinical trial and sign the informed consent form.
Exclusion Criteria
2. Those with AST or ALT levels exceeding 10 times the upper normal limit.
3. Individuals actively involved in dieting or undergoing intense exercise therapy for weight management purposes.
4. Participants with a history of surgical weight loss procedures (e.g., bariatric surgery) or those scheduled for medical or surgical interventions for weight loss during the study period.
5. Individuals with endocrine disorders that may affect body weight (e.g., hypothyroidism, Cushing's syndrome) or those with TSH levels below 0.1uU/ml or above 10.0uU/ml in screening tests.
6. Individuals presenting evidence of chronic hepatitis, including B or C hepatitis (For B or C hepatitis, individuals with positive HBsAg or positive HCV Ab in screening tests and positive HCV RNA are included).
7. Those with a history of alcohol consumption exceeding 210 grams per week for males or 140 grams per week for females within the past year.
8. Individuals who have undergone liver transplantation.
9. Those undergoing renal dialysis or with creatinine levels exceeding twice the upper limit of normal.
10. Individuals in a medically unstable condition to the extent that they cannot participate in the clinical trial based on physical examinations across various organ systems, encompassing cardiovascular, respiratory, gastrointestinal, hepatic-biliary, metabolic, endocrine, renal-urinary, nervous, psychiatric, and other systems.
11. Individuals diagnosed with and treated for malignant tumors within the past 5 years (excluding basal cell carcinoma or squamous cell carcinoma of the skin, provided it has been determined as "cured" after surgery or treatment at the investigator's discretion).
12. Pregnant or lactating women or fertile women who do not consent to using effective contraceptive methods during the study period (oral contraceptives are not considered an effective contraceptive method).
13. Patients currently receiving levodopa.
14. Individuals with genetic conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
15. Individuals with a history of significant alcohol or substance misuse within the past year.
16. hose who have taken medications containing UDCA (Ursodeoxycholic acid), dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethendixoybiphenyl-2,2'-dicarboxylate (DDB), or silymarin components within 4 weeks before the first dose.
17. Those who have taken vitamin E (≥ 800 IU/day), received pioglitazone therapy, or used drugs approved for NASH treatment within 12 weeks before the first dose (exceptions granted if a stable dosage has been maintained for the past 24 weeks).
18. Those who have taken medications affecting body weight within 12 weeks before the first dose, including obesity treatments (absorption inhibitors and appetite suppressants), antidepressants, contraceptives, oral steroids, amphetamines, phentermine, sibutramine, female hormones, thyroid hormones, etc. (exceptions granted if a stable dosage has been maintained for the past 24 weeks).
19. Other individuals deemed unsuitable by the Principal Investigator
20. Those who have taken investigational drugs for other clinical trials within the last 6 months.
19 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celltrion Pharm, Inc.
INDUSTRY
Yoon Jun Kim
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yoon Jun Kim
Coordinating Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
YoonJun Kim, MD.PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMTGODEX_001
Identifier Type: -
Identifier Source: org_study_id